Terms: = Lymphoma AND TP53, TRP53, 7157, ENSG00000141510, P04637, LFS1, P53 AND Treatment
1345 results:
1. XPO1 blockade with KPT-330 promotes apoptosis in cutaneous T-cell lymphoma by activating the p53-p21 and p27 pathways.
Chakravarti N; Boles A; Burzinski R; Sindaco P; Isabelle C; McConnell K; Mishra A; Porcu P
Sci Rep; 2024 Apr; 14(1):9305. PubMed ID: 38653804
[TBL] [Abstract] [Full Text] [Related]
2. Chronic Lymphocytic Leukemia/Small Lymphocytic lymphoma, Version 2.2024.
Wierda WG; Brown J; Abramson JS; Awan F; Bilgrami SF; Bociek G; Brander D; Cortese M; Cripe L; Davis RS; Eradat H; Fakhri B; Fletcher CD; Gaballa S; Hamid MS; Hill B; Kaesberg P; Kahl B; Kamdar M; Kipps TJ; Ma S; Mosse C; Nakhoda S; Parikh S; Schorr A; Schuster S; Seshadri M; Siddiqi T; Stephens DM; Thompson M; Ujjani C; Valdez R; Wagner-Johnston N; Woyach JA; Sundar H; Dwyer M
J Natl Compr Canc Netw; 2024 Apr; 22(3):175-204. PubMed ID: 38626800
[TBL] [Abstract] [Full Text] [Related]
3. Novel PIKfyve/Tubulin Dual-target Inhibitor as a Promising Therapeutic Strategy for B-cell Acute Lymphoblastic Leukemia.
Lu Z; Lai Q; Li ZF; Zhong MY; Jiang YL; Feng LY; Zha J; Yao JW; Li Y; Deng XM; Xu B
Curr Med Sci; 2024 Apr; 44(2):298-308. PubMed ID: 38619682
[TBL] [Abstract] [Full Text] [Related]
4. Mutation landscape in Chinese nodal diffuse large B-cell lymphoma by targeted next generation sequencing and their relationship with clinicopathological characteristics.
Cao B; Sun C; Bi R; Liu Z; Jia Y; Cui W; Sun M; Yu B; Li X; Zhou X
BMC Med Genomics; 2024 Apr; 17(1):84. PubMed ID: 38609996
[TBL] [Abstract] [Full Text] [Related]
5. Full-spectral genome analysis of natural killer/T cell lymphoma highlights impacts of genome instability in driving its progression.
Chen Z; Huang H; Hong H; Huang H; Weng H; Yu L; Xiao J; Wang Z; Fang X; Yao Y; Yue JX; Lin T
Genome Med; 2024 Apr; 16(1):48. PubMed ID: 38566223
[TBL] [Abstract] [Full Text] [Related]
6. Matching-Adjusted Indirect Comparison of Brexucabtagene Autoleucel (ZUMA-2) and Pirtobrutinib (BRUIN) in Patients with Relapsed/Refractory Mantle Cell lymphoma Previously Treated with a Covalent Bruton Tyrosine Kinase Inhibitor.
Salles G; Chen JMH; Zhang I; Kerbauy F; Wu JJ; Wade SW; Nunes A; Feng C; Kloos I; Peng W; Snider JT; Maciel D; Chan K; Keeping S; Shah B
Adv Ther; 2024 May; 41(5):1938-1952. PubMed ID: 38494543
[TBL] [Abstract] [Full Text] [Related]
7. Activity of venetoclax in patients with relapsed or refractory chronic lymphocytic leukaemia: analysis of the VENICE-1 multicentre, open-label, single-arm, phase 3b trial.
Kater AP; Arslan Ö; Demirkan F; Herishanu Y; Ferhanoglu B; Diaz MG; Leber B; Montillo M; Panayiotidis P; Rossi D; Skarbnik A; Tempescul A; Turgut M; Mellink CH; van der Kevie-Kersemaekers AF; Lanham S; Sale B; Del Rio L; Popovic R; Chyla BJ; Busman T; Komlosi V; Wang X; Sail K; Pena GE; Vizkelety T; Forconi F
Lancet Oncol; 2024 Apr; 25(4):463-473. PubMed ID: 38467131
[TBL] [Abstract] [Full Text] [Related]
8. Inotuzumab in Older Patients with Newly Diagnosed Acute Lymphoblastic Leukemia-A Podcast.
Jabbour EJ; Stelljes M
Target Oncol; 2024 Mar; 19(2):135-141. PubMed ID: 38457052
[TBL] [Abstract] [Full Text] [Related]
9. Fisetin nanoparticles based on cells cycle and apoptosis intervention for the treatment of lymphoma and leukemia.
Yang T; Gou H; Lin T; Yang Y; Jin X; Dong T; Zhang Y; Chen X
Int J Pharm; 2024 Apr; 654():123971. PubMed ID: 38452832
[TBL] [Abstract] [Full Text] [Related]
10. Dynamic monitoring of circulating tumor DNA reveals outcomes and genomic alterations in patients with relapsed or refractory large B-cell lymphoma undergoing CAR T-cell therapy.
Zou H; Liu W; Wang X; Wang Y; Wang C; Qiu C; Liu H; Shan D; Xie T; Huang W; Sui W; Yi S; An G; Xu Y; Ma T; Wang J; Qiu L; Zou D
J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38443094
[TBL] [Abstract] [Full Text] [Related]
11. Hairy cell leukemia 2024: Update on diagnosis, risk-stratification, and treatment-Annual updates in hematological malignancies.
Troussard X; Maître E; Paillassa J
Am J Hematol; 2024 Apr; 99(4):679-696. PubMed ID: 38440808
[TBL] [Abstract] [Full Text] [Related]
12. Naringenin Induces Cellular Apoptosis in Melanoma Cells
Fernando PDSM; Zhen AX; Piao MJ; Herath HMUL; Kang KA; Yoon SP; Boo HJ; Hyun CL; Hyun JW
Anticancer Res; 2024 Mar; 44(3):1079-1086. PubMed ID: 38423648
[TBL] [Abstract] [Full Text] [Related]
13. Updated overall survival and circulating tumor DNA analysis of ensartinib for crizotinib-refractory ALK-positive NSCLC from a phase II study.
Zheng J; Wang T; Yang Y; Huang J; Feng J; Zhuang W; Chen J; Zhao J; Zhong W; Zhao Y; Zhang Y; Song Y; Hu Y; Yu Z; Gong Y; Chen Y; Ye F; Zhang S; Cao L; Fan Y; Wu G; Guo Y; Zhou C; Ma K; Fang J; Feng W; Liu Y; Zheng Z; Li G; Wang H; Cang S; Wu N; Song W; Liu X; Zhao S; Ding L; Selvaggi G; Wang Y; Xiao S; Wang Q; Shen Z; Zhou J; Zhou J; Zhang L
Cancer Commun (Lond); 2024 Apr; 44(4):455-468. PubMed ID: 38421881
[TBL] [Abstract] [Full Text] [Related]
14. Biomarker analysis of the ASPEN study comparing zanubrutinib with ibrutinib for patients with Waldenström macroglobulinemia.
Tam CS; Opat S; D'Sa S; Jurczak W; Lee HP; Cull G; Owen RG; Marlton P; Wahlin BE; García-Sanz R; McCarthy H; Mulligan S; Tedeschi A; Castillo JJ; Czyż J; Fernández De Larrea C; Belada D; Libby E; Matous J; Motta M; Siddiqi T; Tani M; Trněný M; Minnema MC; Buske C; Leblond V; Treon SP; Trotman J; Wu B; Yu Y; Shen Z; Chan WY; Schneider J; Allewelt H; Cohen A; Dimopoulos MA
Blood Adv; 2024 Apr; 8(7):1639-1650. PubMed ID: 38315878
[TBL] [Abstract] [Full Text] [Related]
15. Steroid hormone receptor based gene delivery systems as potential oral cancer therapeutics.
Bhattacharya D; Bharati MR; Sakhare K; Khandelia P; Banerjee R; Narayan KP
Biomed Mater; 2024 Feb; 19(2):. PubMed ID: 38290150
[TBL] [Abstract] [Full Text] [Related]
16. Real-world Effectiveness of Azacitidine in treatment-Naive Patients With Higher-risk Myelodysplastic Syndromes.
Rajakumaraswamy N; Gandhi M; Wei AH; Sallman DA; Daver NG; Mo S; Iqbal S; Karalliyadda R; Chen M; Wang Y; Vyas P
Clin Lymphoma Myeloma Leuk; 2024 Apr; 24(4):260-268.e2. PubMed ID: 38216397
[TBL] [Abstract] [Full Text] [Related]
17. An effective treatment and suspicious adverse reaction to Ibrutinib in a patient diagnosed with splenic B-cell lymphoma/leukaemia with prominent nucleoli: A first case report.
Shen MX; Li FL; Luo XS; Wang ZM
Medicine (Baltimore); 2023 Dec; 102(52):e36022. PubMed ID: 38206706
[TBL] [Abstract] [Full Text] [Related]
18. Bifidobacterium longum SX-1326 ameliorates gastrointestinal toxicity after irinotecan chemotherapy via modulating the p53 signaling pathway and brain-gut axis.
Yue F; Zeng X; Wang Y; Fang Y; Yue M; Zhao X; Zhu R; Zeng Q; Wei J; Chen T
BMC Microbiol; 2024 Jan; 24(1):8. PubMed ID: 38172689
[TBL] [Abstract] [Full Text] [Related]
19. Outcomes of intensive and nonintensive blast-reduction strategies in accelerated and blast-phase MPN.
Davidson MB; Kennedy JA; Capo-Chichi JM; Shi Y; Xu W; Cheung V; Arruda A; Bankar A; Richard-Carpentier G; Chan S; Maze D; Minden MD; Schimmer AD; Schuh AC; Sibai H; Yee K; Tierens A; Viswabandya A; Gupta V
Blood Adv; 2024 Mar; 8(5):1281-1294. PubMed ID: 38170760
[TBL] [Abstract] [Full Text] [Related]
20. Selectively targeting BCL6 using a small molecule inhibitor is a potential therapeutic strategy for ovarian cancer.
Wu M; Xie J; Xing Y; Zhang L; Chen H; Tang B; Zhou M; Lv S; Huang D; Jian S; Zhou C; Liu M; Guo W; Chen Y; Yi Z
Int J Biol Sci; 2024; 20(2):486-501. PubMed ID: 38169532
[TBL] [Abstract] [Full Text] [Related]
[Next]
